1. Introduction {#sec1-medsci-08-00001}
===============

Lung cancer (LC), as the second most common cancer in the world, has the highest mortality rate. Specific biomarkers for its diagnostics, treatment, and prognosis are still under further investigation \[[@B1-medsci-08-00001]\], and the incidence of LC continues to increase in China \[[@B2-medsci-08-00001],[@B3-medsci-08-00001]\]. Concurrently, LC is the leading cause of cancer death in China \[[@B4-medsci-08-00001]\]. Although much research effort has been made in improving treatment for LC in recent decades, a survival rate of five years is still less than 20% \[[@B5-medsci-08-00001]\]. There are two main pathological types of LC: small cell lung cancer (SCLC) accounting for about 85% and non-small cell lung cancer (NSCLC) accounting for about 13%--15% \[[@B6-medsci-08-00001]\]. The main symptoms of LC are coughing, hemoptysis, dyspnea, and fatigue. Traditional Chinese medicine (TCM), as an important part of the healthcare system in China, has gradually gained popularity both at home and abroad \[[@B7-medsci-08-00001]\]. There is a general consensus that TCM produces therapeutic effects in a holistic manner \[[@B8-medsci-08-00001]\]; besides, multi-target therapy is more effective than single therapy in combating polygenic diseases \[[@B9-medsci-08-00001]\].

With the development of systems biology, network biology, and pharmacology, Andrew L. Hopkins proposed the concept of network pharmacology \[[@B10-medsci-08-00001]\]. Network pharmacology studies the treatment or influence of drugs on diseases from the network level, and reveals the synergism law of multi-component drugs, so as to discover the high efficiency and low toxicity of multi-target drugs. Therefore, from the molecular level, the idea of TCM is consistent with those of network pharmacology \[[@B11-medsci-08-00001]\].

In recent years, TCMs have been widely applied in the treatment of cancers in China and beyond. XQD, as a classic herbal formula, was created by Huang Yuanyu in the Qing Dynasty from "Si Sheng Xin Yuan". XQD is mainly used to treat diseases of lung and stomach system. XQD is composed of eight medicinal herbs: Licorice (LO), Schisandra chinensis (SC), Poria cocos (PC), Pinellia ternata (Thunb) Breit (AT), Citrus reticulata (CR), Fritillaria cirrhosa D. Don (FR),Paeoniae radix alba (PR), and Amygdalus communis vas (AC). XQD is commonly used to treat lung diseases such as cough, asthma, and lung cancer \[[@B12-medsci-08-00001],[@B13-medsci-08-00001]\]. Clinical experiments found that Xiaqi Decoction can also treat the acute exacerbation of chronic bronchitis \[[@B14-medsci-08-00001]\]. Furthermore, it was found that the total effective rate of the experimental group was 86.7%, which was significantly higher than that of the control group (63.3%), after clinical comparison experiments \[[@B15-medsci-08-00001]\]. However, the effective compounds, targets and pharmacological mechanisms of XQD in the treatment of lung cancer remained unclear. Therefore, in this paper, a network pharmacology approach, functional gene pathway analysis, network analysis, and other comprehensive methods were used to reveal XQD-related active compounds, key therapeutic targets, and the molecular mechanism of action for LC.

2. Materials and Methods {#sec2-medsci-08-00001}
========================

2.1. Collection of XQD Chemical Ingredients {#sec2dot1-medsci-08-00001}
-------------------------------------------

TCMSP database (<http://sm.nwsuaf.edu.cn/lsp/tcmsp.php>.) is a traditional Chinese medicine systems pharmacology database and analysis platform \[[@B16-medsci-08-00001]\]. To determine the chemical ingredients of the eight herbs contained in XQD, we performed a search by TCMSP. In order to maximize the chances of finding the fully active compounds, we set two conditions as the criteria for screening these active compounds: oral bioavailability (OB) and drug-likeness (DL), which are the two most important indicators of evaluating ADME characteristics via bioinformatics.

2.2. Target Selection and Herb-Ingredient-Target Network Construction of XQD {#sec2dot2-medsci-08-00001}
----------------------------------------------------------------------------

After discovering 112 active ingredients of eight traditional Chinese medicines of XQD, the next important step was to identify their molecular targets and trigger a series of biological effects. The potential targets of XQD were also identified from DrugBank database \[[@B17-medsci-08-00001]\] and the database of our research group \[[@B18-medsci-08-00001]\]. Herb-ingredient-target network with Cytoscape3.7 software was constructed. Nodes in the network were herbs, ingredients and targets. Edges were used to connect herbs with ingredients, active ingredients, and act targets to show the relationship between herbs, active ingredients, and targets in order to explore the multiple pharmacological mechanisms of XQD based on the constructed network.

2.3. Collection of Therapeutic Targets for LC {#sec2dot3-medsci-08-00001}
---------------------------------------------

Therapeutic targets for LC were collected from the following four databases: NCBI database \[[@B19-medsci-08-00001]\], TTD database \[[@B20-medsci-08-00001]\], OMIM database \[[@B21-medsci-08-00001]\], and DrugBank database \[[@B17-medsci-08-00001]\]. Using "Lung cancer" to search in the four databases mentioned above, the duplicate targets were eliminated, and 228 targets related to human LC were finally obtained.

2.4. Protein-Protein Interaction Data {#sec2dot4-medsci-08-00001}
-------------------------------------

Protein--protein interaction (PPI) data were from STRING database \[[@B22-medsci-08-00001]\] and an auxiliary elucidation system for the TCM mechanism of our team laboratory, which realized the automatic establishment of biological network model \[[@B18-medsci-08-00001]\]. Entity grammar systems is a formal grammar system \[[@B23-medsci-08-00001]\], which is extended to Chomsky generative grammar system and has been used for the analysis of multiple mechanisms of action of traditional Chinese medicine. It has the characteristics of high efficiency and flexibility, and is suitable for the study of complex biological systems. The ID type of protein is converted to UniProt ID \[[@B24-medsci-08-00001]\].

2.5. Herb-Ingredient-LC Therapeutic Target Network Analysis {#sec2dot5-medsci-08-00001}
-----------------------------------------------------------

The ingredients-target network was mapped to LC-related gene network. Furthermore the interaction network between the target of XQD and LC-related genes was established. If the chemical components of XQD overlap with the therapeutic targets of LC, then these targets are the direct targets of XQD for LC treatment. If the chemical targets of XQD act on the therapeutic targets of LC through one or two protein interactions, then these targets are indirect targets of XQD for LC. The direct and indirect targets of XQD on LC were found, and the mechanism was determined. In this network, the nodes represent Chinese medicine, ingredients, targets or genes and LC, and the links between these nodes. "Degree value" is the number of edges associated with it. Targets with connectivity greater than twice the average number of node degrees are selected as key nodes in the network \[[@B25-medsci-08-00001]\].

2.6. Pathway Enrichment Analysis {#sec2dot6-medsci-08-00001}
--------------------------------

KEGG (Kyoto Encyclopedia of Genes and Genomes) is a database of genome decipherment. The KEGG pathway was used to analyze the main pathways of XQD acting on 41 targets of LC. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks \[[@B26-medsci-08-00001]\], which was used to integrate the KEGG pathways \[[@B27-medsci-08-00001]\].

2.7. Relationship Analysis Between LC Targets and Immunological Targets Affected by XQD {#sec2dot7-medsci-08-00001}
---------------------------------------------------------------------------------------

41 genes of LC affected by XQD were searched in GeneCards database \[[@B28-medsci-08-00001]\] to find the expression of genes (targets) in human immune tissues and cells. Chi-square test was used to screen the genes significantly expressed in immune tissues and cells. We constructed a network between the selected genes and immune tissues and cells, to explore the mechanism of the key genes regulating LC and immunity.

3. Results {#sec3-medsci-08-00001}
==========

3.1. OB Prediction and DL Calculation {#sec3dot1-medsci-08-00001}
-------------------------------------

According to TCMSP database of TCM systematic pharmacology and analysis platform, the chemical ingredients of the eight traditional Chinese medicines of XQD were identified. In order to obtain the potential active ingredients of XQD, the chemical were evaluated and screened using OB ≥ 30% \[[@B29-medsci-08-00001]\], DL ≥ 0.18 \[[@B30-medsci-08-00001]\], respectively. The chemical ingredients of eight traditional Chinese medicines in XQD were as follows: 92 in LO,13 in AT,15 in PC,19 in AC,13 in FR,8 in SC,13 in PR,5 in CR. In order to further screen the active ingredients of LO, the OB of which was increased to more than 50%. Eventually, 112 active ingredients were screened out ([Table 1](#medsci-08-00001-t001){ref-type="table"}).

3.2. Target Selection and Herb-Ingredient-Target Network Construction of XQD {#sec3dot2-medsci-08-00001}
----------------------------------------------------------------------------

Ninety-six potential targets were obtained from TCMSP and our laboratory database. Cytoscape software was used to construct a network of herb-ingredient-target. The nodes in the network were Chinese herbs, components, and targets; in addition, the edge of the network represented the relationship between herb--component and component--target. By introducing 8 herbs, 112 ingredients, and 96 targets into Cytoscape, three kinds of nodes were connected to construct a network of traditional Chinese medicines, active ingredients, and targets, as shown in [Figure 1](#medsci-08-00001-f001){ref-type="fig"}.

The network consists of 8 herbs, 112 chemical ingredients, 96 targets, 234 nodes, and 1498 edges. The Centiscape2.2 plugin is used to screen the key nodes in the network. Centrality is used to screen the targets. Using Centiscape2.2, we can calculate Degree Centrality (DC), Closeness Centrality (CC), and Betweenness Centrality (BC). Degree value denotes the number of routes connected to the node in the network. In this network, Degree = 13.833, Betweenness Centrality = 0.008, Closeness Centrality = 0.365. Among 50 of 112 active ingredients are active ingredients with degree greater than 14 and degree of 9 active ingredients is greater than twice the average degree in [Table 2](#medsci-08-00001-t002){ref-type="table"}. Among the 96 targets, degree of 29 targets is more than 14 and degree of 19 targets is more than twice the average in [Table 3](#medsci-08-00001-t003){ref-type="table"}. Therefore, these 19 targets are very likely to be the key targets for XQD to play a therapeutic role.

In the herb-ingredient-target network, 45.5% of the chemical ingredients had more than 14 targets, and 12 of them had more than 28 targets in [Table 3](#medsci-08-00001-t003){ref-type="table"}. This indicated that most of the chemical ingredients in XQD could simultaneously act on multiple targets to play a combined therapeutic role. For example, Beta-sitosterol, a chemical ingredients contained in Fritillaria chuanxiong, AT, and PR, has the most targets and can interact with 49 targets. Secondly, the number of targets of Kaempferol in PR and L-SPD in AC was 44. Beta-sitosterol is a plant derived nutrient with anticancer properties against LC, stomach cancer, ovarian cancer, and leukemia. Studies have shown that BS interfere with multiple cell signaling pathways, including cell cycle, apoptosis, survival, invasion, angiogenesis, and metastasis \[[@B31-medsci-08-00001]\]. Kaempferol is the most common flavonoid compound, which has inhibitory effects on LC \[[@B32-medsci-08-00001]\], ovarian cancer \[[@B33-medsci-08-00001]\], breast cancer \[[@B34-medsci-08-00001]\], and many other tumors.

In the network, the highest degree target was AR, corresponding to 87 chemical compounds. Positive expression of AR might be correlated with the progression and the lymph node metastasis of lung cancer \[[@B35-medsci-08-00001]\]. AR could inhibit the proliferation and survival of cancer cells by up-regulating PTEN directly \[[@B36-medsci-08-00001]\]. Secondly, ESR1 had 74 chemical ingredients that can act on this target. In non-small cell lung cancer, ESR1 can be combined with EGFR, showing enhanced antiproliferation effects \[[@B37-medsci-08-00001]\]. Therefore, it was speculated that these key components and targets were closely related to the mechanism of XQD in the treatment of LC.

3.3. Construction of PPI Network in XQD {#sec3dot3-medsci-08-00001}
---------------------------------------

96 targets of XQD were imported into STRIING database, and the species were limited to human beings. Some proteins did not interact with each other, which were not reflected in the interaction network. The highest confidence level with score greater than 0.9 was selected to obtain the protein network. Average degree value = 5.15, and 13 non-interactive targets were excluded. In PPI networks with 82 targets, the size and color of the target were set to reflect the Degree size, the minimum value of Degree = 1, and the maximum value of Degree = 14. The thickness of the table was set to reflect the combine size in [Figure 2](#medsci-08-00001-f002){ref-type="fig"}.

The PPI network ([Figure 2](#medsci-08-00001-f002){ref-type="fig"}) of 82 targets included 82 nodes and 207 edges. Eight targets with a degree greater than twice the median were MAPK3 (Degree = 14), JUN (Degree = 12), TP53 (Degree = 12), HSP90AA1 (Degree = 11), TNF (Degree = 11), ESR1 (Degree = 11), F2 (Degree = 11), CHRM2 (Degree = 11). A total of 8 central targets were obtained. These eight targets play a key role in the protein network and become the hub connecting other nodes in the network. Among them, the degree of MAPK3 (mitogen-activated protein kinase 3) was the highest (Degree = 14). This indicates that these targets play a key role in the network and become the hub connecting other targets in the network.

3.4. Constructing the Network of Herb-Ingredient-Target-LC Therapeutic Target {#sec3dot4-medsci-08-00001}
-----------------------------------------------------------------------------

To construct the network of XQD and lung cancer treatment, 91 of the 112 chemical ingredients of XQD act on 41 targets of LC through direct or indirect protein interaction. Degree = 8.09, Betweenness centrality = 0.012, Closeness centrality = 0.356. Ultimately, as shown in [Figure 3](#medsci-08-00001-f003){ref-type="fig"}, the degree value of 25 components was more than 8. There are 25 key components whose degree value is greater than the average degree value ([Table 4](#medsci-08-00001-t004){ref-type="table"}). These components could be considered as the key compounds of XQD in the treatment of LC. In the network ([Figure 3](#medsci-08-00001-f003){ref-type="fig"}), we screened 14 direct targets ([Table 5](#medsci-08-00001-t005){ref-type="table"}) and 27 indirect targets ([Table 6](#medsci-08-00001-t006){ref-type="table"}) for LC.

They were mainly: Beta-sitosterol (degree = 17) in PR, AT and FR can act on 14 targets of LC. Kaempferol in PR (degree = 14) acts on 13 targets of LC. Beta-sitosterol is present in PR, having anti-tumor, anti-microbial, and immunomodulatory activities \[[@B38-medsci-08-00001]\]. In vitro studies showed that Beta-sitosterol increased the number of viable peripheral blood mononuclear cell (PBMC) and activated swine dendritic cells (DCs) in culture \[[@B39-medsci-08-00001]\]. Beta-sitosterol (β-sitosterol) induced G0/G1 cell cycle arrest and inhibited cell proliferation in A549 cells. These results indicate that beta-sitosterol may serve as novel targets for the treatment of NSCLC \[[@B40-medsci-08-00001]\]. Bio-assay guided fractionation showed the presence of phytosteols (β-sitosterol) which significantly inhibited the growth of A549 cells and promoted apoptosis alone or in combination. This study ensures that these phytosterols, alone or in combination, can be considered as safe and potential drug candidates for LC treatment \[[@B41-medsci-08-00001]\]. Kaempferol in PR can act on 13 targets of LC. MEK-MAPK is a requirement for kaempferol-induced cell death machinery in A549 cells \[[@B32-medsci-08-00001]\]. Cavidine (degree = 13) in AT acts on 12 targets of LC. Cavidine exists in AT and has significant anti-inflammatory effect, which inhibits the production of proinflammatory cytokines TNF-alpha and IL-6 \[[@B42-medsci-08-00001]\]. At the same time, Cavidine has anti-inflammatory activity to prevent inflammatory injury induced by lipopolysaccharide (LPS) \[[@B42-medsci-08-00001],[@B43-medsci-08-00001]\].

Naringenin (degree = 12) in LO and formononetin (degree = 11) in AC can act on 10 targets of LC, respectively. The cumulative effect of these four ingredients on the number of therapeutic targets for LC is 22. Studies have shown that Naringenin, a natural product that is mainly present in LO, may contribute to cancer prevention. There are many advantages compared to traditional chemotherapeutic drugs, such as low toxicity, which can also inhibit the number of lung cancer cells metastasis by regulating immunity \[[@B44-medsci-08-00001]\]. Thus, it has a potential to inhibit lung cancer \[[@B44-medsci-08-00001],[@B45-medsci-08-00001]\]. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells, with no detectable inhibitory effects on cell proliferation of normal lung fibroblast cells \[[@B46-medsci-08-00001]\]. Formononetin in AC was investigated the anti-proliferative effects on human non-small cell lung cancer (NSCLC). It inhibits proliferation of two NSCLC cell lines (A549 and nci-h23), induces G1 phase cell cycle arrest, and promotes NSCLC cell apoptosis. The results demonstrated that formononetin might be a potential chemopreventive drug for lung cancer therapy through induction of cell cycle arrest and apoptosis in NSCLC cells \[[@B47-medsci-08-00001]\]. Baicalein (degree = 10) in AT is a widely used Chinese herbal medicine, traditionally used as anti-inflammatory and anti-cancer therapy. Baicalein significantly decreased lung cancer proliferation in H-460 cells in a dose-dependent induction in apoptosis. This was the first time that baicalin had been effective in vitro and in vivo in NSCLC \[[@B48-medsci-08-00001]\]. Experimental studies had shown that Baicalein induced cell cycle arrest and apoptosis in human lung squamous carcinoma CH27 cells \[[@B49-medsci-08-00001]\].

3.5. Pathway Analysis of XQD Acting on LC Therapeutic Targets {#sec3dot5-medsci-08-00001}
-------------------------------------------------------------

In order to investigate the biological effects of 41 targets of XQD for LC, 41 genes were inserted by ClueGO plug in Cytoscape. The target-pathway network graph ([Figure 4](#medsci-08-00001-f004){ref-type="fig"}) was obtained by setting a path that only showed *p* value ≤ 0.05 and in which the number of genes in the pathway was more than three. We analyzed the data and relevant biological processes for LC, choosing top ten remarkable significant pathways ([Figure 5](#medsci-08-00001-f005){ref-type="fig"}) according to the *p* value for further study. The first four pathways with the largest number of gene enrichment were cell senescence \[[@B50-medsci-08-00001],[@B51-medsci-08-00001]\], FoxO signaling pathway \[[@B52-medsci-08-00001],[@B53-medsci-08-00001]\], HIF-1 (hypoxia inducible factor) signaling pathway \[[@B54-medsci-08-00001]\], and estrogen signaling pathway \[[@B55-medsci-08-00001],[@B56-medsci-08-00001]\]. Thus pro-senescence therapies may represent a new treatment for lung cancer \[[@B57-medsci-08-00001]\]. FoxO play a vital role in cell fate determination, and the subfamily is also considered to play a key role in cancer as a cancer inhibitor. In the process of apoptosis, FoxO participates in mitochondrial dependent and independent processes, triggering the expression of death receptor ligands such as Fas ligand, TNF apoptotic ligand and Bcl-XL \[[@B58-medsci-08-00001]\]. HIF-1 signaling pathway inhibits cell viability and induces cell apoptosis \[[@B55-medsci-08-00001]\]. The results indicate that HIF-1α signaling pathway plays an important role in the regulation of TNF-α-induced proliferation and metastasis of A549 cells in NSCLC \[[@B59-medsci-08-00001]\]. In addition, there are five other pathways: p53 signaling pathway \[[@B60-medsci-08-00001],[@B61-medsci-08-00001]\], cellcycle, ErbB signaling pathway \[[@B62-medsci-08-00001]\], IL-17 signaling pathway \[[@B51-medsci-08-00001],[@B52-medsci-08-00001],[@B63-medsci-08-00001],[@B64-medsci-08-00001]\], small cell lung cancer, vascular endothelial growth factor signaling pathway \[[@B65-medsci-08-00001],[@B66-medsci-08-00001]\]. All of them are closely related to the occurrence of lung cancer, apoptosis of tumor cells, and immune function. Moreover, we drew a histogram of the 10 pathways screened, showing the number of genes enriched in each pathway.

3.6. Constructing Target-Immune Tissues and Cell Network {#sec3dot6-medsci-08-00001}
--------------------------------------------------------

The 41 LC genes affected by XQD were placed in the GeneCards database to search for the expression of targets (genes) in human tissues and cells. With the chi-square test, finally eight therapeutic targets for LC are significantly expressed in immune tissues and cells. The data of eight LC treatment targets and 14 immune tissues and cells were introduced into Cytoscape 3.7.1 to construct a network between target-immune ([Figure 5](#medsci-08-00001-f005){ref-type="fig"}) for further analysis. The size and color of the target were set to reflect the Degree size, and the thickness of the table was set to reflect the combine size. In this network, HLA-B, CASP8, and MAPK14 three targets of XQD, had the most obvious relationship with immune tissues and cells. From [Figure 6](#medsci-08-00001-f006){ref-type="fig"} and [Table 7](#medsci-08-00001-t007){ref-type="table"}, it can be seen that the expression level of HLA-B in 14 immune tissues and cells is significantly higher than that of the other seven targets. The expression of CASP8 in NK cells, CD8+T cells and CD4+T cells is significantly higher than that in the other 11 tissues and cells. MAPK14 also is more significantly expressed in 14 kinds of immune tissues and cells. Therefore, we concluded that the three targets of HLA-B, CASP8, and MAPK14 are the immunological targets of XQD for the treatment of LC.

4. Discussion {#sec4-medsci-08-00001}
=============

HLA-B is an important target of XQD in the treatment of LC and also an immunological target. HLA-B is one of the MHC I. MHC is the major histocompatibility complex of human, namely human Leukocyte Antigen HLA, which participates in antigen presentation, specifically recognizes TCR, and plays a key role in the activation of T cells. HLA-B belongs to HLA-I molecule, which is widely distributed on the surface of all nucleated cells and closely related to human immunity \[[@B67-medsci-08-00001]\]. While complexing with antigenic peptides, HLA-B molecules initiate CD8+T cell responses via interaction with the T cell receptor (TCR) and coreceptor CD8 \[[@B68-medsci-08-00001]\]. Similarly, the expression of HLA-B in cancer cells was helpful in activating the activation and proliferation of CD8+T cells \[[@B69-medsci-08-00001]\].

CASP8 is a member of the caspase-cysteine protease family and plays an important role in the development of cancer \[[@B70-medsci-08-00001]\]. It has been reported that 79% of NSCLC cell lines lack Caspase-8, about 35% of SCLC and 18% of bronchogenic carcinoma have promoter methylation of CASP8 \[[@B71-medsci-08-00001]\]. Caspase-8 can activate Caspase downstream of almost all apoptotic cascades and induce apoptosis \[[@B72-medsci-08-00001],[@B73-medsci-08-00001]\], as a caspase-dependent apoptotic pathway promoter, which has been extensively studied under the trigger of death receptor of TNF-R1 \[[@B74-medsci-08-00001]\]. CASP8 has immuno-regulatory functions \[[@B75-medsci-08-00001]\], which regulates T cell activation and proliferation \[[@B76-medsci-08-00001]\], positive regulation of macrophage differentiation \[[@B77-medsci-08-00001]\], and activation of natural killer cells \[[@B78-medsci-08-00001]\].

MAPK14 activation could be a common response of most cancer cells. The family of p38 has 4 different isoforms (MAPK11/p38β, MAPK12/p38γ, MAPK13/p38δ, and MAPK14/p38α) \[[@B79-medsci-08-00001]\], among which MAPK14 is the most abundant and widely expressed \[[@B80-medsci-08-00001]\]. MAPK14 is an important apoptotic inducer, TNF-α, TGF-β and oxidative stress activate MAPK14 signaling pathway to induce apoptosis \[[@B81-medsci-08-00001],[@B82-medsci-08-00001],[@B83-medsci-08-00001]\], and exert its anti-tumor effect \[[@B84-medsci-08-00001]\]. Reactivation of the p38α MAPK pathway might be a useful therapy for LC \[[@B85-medsci-08-00001]\].

Studies have shown that Fas-mediated increase in the activity of P38MAPK requires the participation of Caspase family members. P38MAPK is the downstream target of Caspase, thus causing target cell apoptosis \[[@B86-medsci-08-00001]\]. Here are the mechanisms of P38MAPK in promoting apoptosis: 1) participating in Fas/FasL-mediated apoptosis \[[@B87-medsci-08-00001]\]; 2) upregulating the expression of TNF-alpha; TNF can induce apoptosis by activating MAPKK upstream of p38MAPK, and ultimately activating p38MAPK \[[@B88-medsci-08-00001]\]. Malignant proliferation of cells or the production of cancer cells are due to the dysfunction of cell proliferation and cell death regulation. Fas/FasL is the most important signal pathway involved in cell apoptosis \[[@B89-medsci-08-00001]\], which is closely related to anti-cancer therapy \[[@B90-medsci-08-00001]\].

XQD involves the biological process of tumor cell apoptosis induced by immune regulation ([Figure 7](#medsci-08-00001-f007){ref-type="fig"}). In stimulating the process of tumor cell apoptosis, XQD plays a role in HLA-B on dendritic cells (MHC I) of mature DC and CD8+T cells at the same time, to activate CD8+T cells in the immune response, to identify tumor antigen and kill tumor cells. After activation, CTL expresses FasL and TNF-α, binds to the Fas and TNFR1 on the surface of tumor cells, and generates FADD, which will conduct the apoptosis signal into the cell and perform CASP8 proteolytic activation, thus initiating the apoptosis process of tumor cells. The apoptotic signal was transmitted to MAPK14 to induce accelerated apoptosis.

As demonstrated in this study, XQD can play a vital role in the treatment of LC by enhancing immunity and mediating apoptosis of cancer cells. One of the characteristics of TCM is to seek the root of the disease. It advocates the idea of strengthening the body and eliminating pathogens in the treatment of diseases. In the mechanism of XQD in the treatment of LC, it can not only activate the function of immune cells and improve the immunity of patients, but also promote the apoptosis of cancer cells. From the molecular mechanism, the advantages of XQD in the treatment of LC are that it reinforces the healthy qi and eliminates the pathogenic factors. In the study of XQD, the practical application of network analysis method was described, and the results show that this method was an effective strategy for the modern research of TCM. The data of herbal ingredients involved in each formula cover a wide range and involve many targets, which in turn provides more directions for the research on the molecular mechanism of the therapeutic effect of TCM formula. Different TCM formulations have different components and targets. The network pharmacology method can better explain the different molecular mechanisms of different formulas for the treatment of various diseases. Although a lot of network pharmacology research has been done in the field of TCM, it has not shown the characteristic advantages of TCM therapy---Fu Zheng Fu Ben and strengthening the immunity. At present, research on LC rarely involve the effects of drugs on immune tissues and cells. This study aims to make up for this deficiency. Using a similar research analysis method, more cancers and tumors can be studied.

5. Conclusions {#sec5-medsci-08-00001}
==============

The study reveals the molecular mechanism of XQD in the treatment of LC from the perspective of network pharmacology. The aim of this study was to analyze the molecular mechanism of the effective components and targets in TCM prescriptions acting on lung cancer and immunity, and to understand the synergistic mechanism and characteristics of TCM from a more comprehensive perspective. The results show that this method can better explain the unique advantages of XQD in the treatment of LC.

While treating LC, XQD can activate (up-regulate) the function of immune cells, promote the apoptosis of tumor cells, and has an active anti-tumor immune effect. Therefore, it is necessary to give full play to the characteristics of TCM in the treatment of cancer: reinforce the healthy qi and eliminate the pathogenic factors. It provides a new idea for the current research of LC treatment, with the aim of treating LC while enhancing immunity.
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![Herb-ingredient-target network. Blue square: herbs, green diamond: ingredients, orange triangle: targets, Blue edges: the relationship between herbs and components; Pink edges: the relationship components herbs and targets.](medsci-08-00001-g001){#medsci-08-00001-f001}

![The protein--protein interaction (PPI) of 82 targets.](medsci-08-00001-g002){#medsci-08-00001-f002}

![The shapes of different colors represent different types of nodes. Blue ellipse represents traditional Chinese medicine, green square represents chemical composition, orange triangle represents the predictive target of XQD, red triangle represents the direct target of XQD for lung cancer treatment, and light blue represents the indirect target of XQD for LC treatment.](medsci-08-00001-g003){#medsci-08-00001-f003}

![Target-pathway network. Small nodes stand for therapeutic targets for lung cancer. Large nodes stand for main pathways based on enrichment analysis.](medsci-08-00001-g004){#medsci-08-00001-f004}

![Main pathways enriched by major targets. The top 10 pathways selected to demonstrate the crucial biological actions of major targets. The abscissa stands for target counts in each pathway, and the ordinate stands for main pathways.](medsci-08-00001-g005){#medsci-08-00001-f005}

![Target size and color settings were used to reflect Degree value size. The larger the shape and the darker the color of the node indicates that the target (gene) could play a role in the more immune tissues and cells.](medsci-08-00001-g006){#medsci-08-00001-f006}

![The target of XQD for LC therapy regulates immune-mediated tumor cell apoptosis. DC, dendritic cell; MHC, Major histocompatibility complex, TCR, T-cell receptor, CTL, Cytotoxic T cells, DD, Death domain, FADD, Fas-associated death domain, TRADD, TNF receptor associated death domain. HLA-B, CASP8 and MAPK14 were three therapeutic targets of XQD for LC.](medsci-08-00001-g007){#medsci-08-00001-f007}

medsci-08-00001-t001_Table 1

###### 

Active ingredients and ADME parameters of Xia Qi Decoction (XQD).

  ID      MOL ID      Molecule Name                                                                                                                                                                   OB/%    DL     Herb
  ------- ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ------ ----------------
  ID001   MOL000359   sitosterol                                                                                                                                                                      36.91   0.75   CR, PR, FR, AC
  ID002   MOL004328   naringenin                                                                                                                                                                      59.29   0.21   CR, LO
  ID003   MOL005100   5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one                                                                                                                        47.74   0.27   CR
  ID004   MOL005815   Citromitin                                                                                                                                                                      86.9    0.51   CR
  ID005   MOL005828   nobiletin                                                                                                                                                                       61.67   0.52   CR
  ID006   MOL001755   24-Ethylcholest-4-en-3-one                                                                                                                                                      36.08   0.76   AT
  ID007   MOL002670   Cavidine                                                                                                                                                                        35.64   0.81   AT
  ID008   MOL002714   baicalein                                                                                                                                                                       33.52   0.21   AT
  ID009   MOL002776   Baicalin                                                                                                                                                                        40.12   0.75   AT
  ID010   MOL000358   beta-sitosterol                                                                                                                                                                 36.91   0.75   AT, FR, PR
  ID011   MOL000449   Stigmasterol                                                                                                                                                                    43.83   0.76   AT, AC
  ID012   MOL005030   gondoic acid                                                                                                                                                                    30.7    0.2    AT, AC
  ID013   MOL000519   coniferin                                                                                                                                                                       31.11   0.32   AT
  ID014   MOL006936   10,13-eicosadienoic                                                                                                                                                             39.99   0.2    AT
  ID015   MOL006937   12,13-epoxy-9-hydroxynonadeca-7,10-dienoic acid                                                                                                                                 42.15   0.24   AT
  ID016   MOL006957   (3S,6S)-3-(benzyl)-6-(4-hydroxybenzyl)piperazine-2,5-quinone                                                                                                                    46.89   0.27   AT
  ID017   MOL003578   Cycloartenol                                                                                                                                                                    38.69   0.78   AT
  ID018   MOL006967   beta-D-Ribofuranoside, xanthine-9                                                                                                                                               44.72   0.21   AT
  ID019   MOL001910   11alpha,12alpha-epoxy-3beta-23-dihydroxy-30-norolean-20-en-28,12beta-olide                                                                                                      64.77   0.38   PR
  ID020   MOL001918   paeoniflorgenone                                                                                                                                                                87.59   0.37   PR
  ID021   MOL001919   (3S,5R,8R,9R,10S,14S)-3,17-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9-hexahydro-1H-cyclopenta\[a\]phenanthrene-15,16-dione                                                   43.56   0.53   PR
  ID022   MOL001921   Lactiflorin                                                                                                                                                                     49.12   0.8    PR
  ID023   MOL001924   paeoniflorin                                                                                                                                                                    53.87   0.79   PR
  ID024   MOL001925   paeoniflorin_qt                                                                                                                                                                 68.18   0.4    PR
  ID025   MOL001928   albiflorin_qt                                                                                                                                                                   66.64   0.33   PR
  ID026   MOL001930   benzoyl paeoniflorin                                                                                                                                                            31.27   0.75   PR
  ID027   MOL000211   Mairin                                                                                                                                                                          55.38   0.78   PR, LO, AC
  ID028   MOL000422   kaempferol                                                                                                                                                                      41.88   0.24   PR
  ID029   MOL000492   (+)-catechin                                                                                                                                                                    54.83   0.24   PR, AC
  ID030   MOL004624   Longikaurin A                                                                                                                                                                   47.72   0.53   SC
  ID031   MOL005317   Deoxyharringtonine                                                                                                                                                              39.27   0.81   SC
  ID032   MOL008956   Angeloylgomisin O                                                                                                                                                               31.97   0.85   SC
  ID033   MOL008957   Schizandrer B                                                                                                                                                                   30.71   0.83   SC
  ID034   MOL008968   Gomisin-A                                                                                                                                                                       30.69   0.78   SC
  ID035   MOL008974   Gomisin G                                                                                                                                                                       32.68   0.83   SC
  ID036   MOL008978   Gomisin R                                                                                                                                                                       34.84   0.86   SC
  ID037   MOL008992   Wuweizisu C                                                                                                                                                                     46.27   0.84   SC
  ID038   MOL001749   ZINC03860434                                                                                                                                                                    43.59   0.35   FR
  ID039   MOL004440   Peimisine                                                                                                                                                                       57.4    0.81   FR
  ID040   MOL009027   Cyclopamine                                                                                                                                                                     55.42   0.82   FR
  ID041   MOL009572   Chuanbeinone                                                                                                                                                                    41.07   0.71   FR
  ID042   MOL009579   ent-(16S)-atisan-13,17-oxide                                                                                                                                                    47.74   0.43   FR
  ID043   MOL009586   isoverticine                                                                                                                                                                    48.23   0.67   FR
  ID044   MOL009588   Korseveriline                                                                                                                                                                   35.16   0.68   FR
  ID045   MOL009589   Korseverinine                                                                                                                                                                   53.51   0.71   FR
  ID046   MOL009593   verticinone                                                                                                                                                                     60.07   0.67   FR
  ID047   MOL009596   sinpemine A                                                                                                                                                                     46.96   0.71   FR
  ID048   MOL009599   songbeinone                                                                                                                                                                     45.35   0.71   FR
  ID049   MOL010921   estrone                                                                                                                                                                         53.56   0.32   AC
  ID050   MOL010922   Diisooctyl succinate                                                                                                                                                            31.62   0.23   AC
  ID051   MOL002211   11,14-eicosadienoic acid                                                                                                                                                        39.99   0.2    AC
  ID052   MOL002372   (6Z,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene                                                                                                    33.55   0.42   AC
  ID053   MOL000953   CLR                                                                                                                                                                             37.87   0.68   AC
  ID054   MOL002311   Glycyrol                                                                                                                                                                        90.78   0.67   AC, LO
  ID055   MOL003410   Ziziphin_qt                                                                                                                                                                     66.95   0.62   AC
  ID056   MOL004355   Spinasterol                                                                                                                                                                     42.98   0.76   AC
  ID057   MOL004841   Licochalcone B                                                                                                                                                                  76.76   0.19   AC, LO
  ID058   MOL004903   liquiritin                                                                                                                                                                      65.69   0.74   AC, LO
  ID059   MOL004908   Glabridin                                                                                                                                                                       53.25   0.47   AC, LO
  ID060   MOL005017   Phaseol                                                                                                                                                                         78.77   0.58   AC, LO
  ID061   MOL007207   Machiline                                                                                                                                                                       79.64   0.24   AC
  ID062   MOL012922   l-SPD                                                                                                                                                                           87.35   0.54   AC
  ID063   MOL000273   (2R)-2-\[(3S,5R,10S,13R,14R,16R,17R)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta\[a\]phenanthren-17-yl\]-6-methylhept-5-enoic acid      30.93   0.81   PC
  ID064   MOL000275   trametenolic acid                                                                                                                                                               38.71   0.8    PC
  ID065   MOL000276   7,9(11)-dehydropachymic acid                                                                                                                                                    35.11   0.81   PC
  ID066   MOL000279   Cerevisterol                                                                                                                                                                    37.96   0.77   PC
  ID067   MOL000280   (2R)-2-\[(3S,5R,10S,13R,14R,16R,17R)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta\[a\]phenanthren-17-yl\]-5-isopropyl-hex-5-enoic acid   31.07   0.82   PC
  ID068   MOL000282   ergosta-7,22E-dien-3beta-ol                                                                                                                                                     43.51   0.72   PC
  ID069   MOL000283   Ergosterol peroxide                                                                                                                                                             40.36   0.81   PC
  ID070   MOL000285   (2R)-2-\[(5R,10S,13R,14R,16R,17R)-16-hydroxy-3-keto-4,4,10,13,14-pentamethyl-1,2,5,6,12,15,16,17-octahydrocyclopenta\[a\]phenanthren-17-yl\]-5-isopropyl-hex-5-enoic acid       38.26   0.82   PC
  ID071   MOL000287   3beta-Hydroxy-24-methylene-8-lanostene-21-oic acid                                                                                                                              38.7    0.81   PC
  ID072   MOL000289   pachymic acid                                                                                                                                                                   33.63   0.81   PC
  ID073   MOL000290   Poricoic acid A                                                                                                                                                                 30.61   0.76   PC
  ID074   MOL000291   Poricoic acid B                                                                                                                                                                 30.52   0.75   PC
  ID075   MOL000292   poricoic acid C                                                                                                                                                                 38.15   0.75   PC
  ID076   MOL000296   hederagenin                                                                                                                                                                     36.91   0.75   PC
  ID077   MOL000300   dehydroeburicoic acid                                                                                                                                                           44.17   0.83   PC
  ID078   MOL005020   dehydroglyasperins C                                                                                                                                                            53.82   0.37   LO
  ID079   MOL005018   Xambioona                                                                                                                                                                       54.85   0.87   LO
  ID080   MOL005012   Licoagroisoflavone                                                                                                                                                              57.28   0.49   LO
  ID081   MOL005007   Glyasperins M                                                                                                                                                                   72.67   0.59   LO
  ID082   MOL005003   Licoagrocarpin                                                                                                                                                                  58.81   0.58   LO
  ID083   MOL005001   Gancaonin H                                                                                                                                                                     50.1    0.78   LO
  ID084   MOL005000   Gancaonin G                                                                                                                                                                     60.44   0.39   LO
  ID085   MOL004993   8-prenylated eriodictyol                                                                                                                                                        53.79   0.4    LO
  ID086   MOL004990   7,2′,4′-trihydroxy-5-methoxy-3-arylcoumarin                                                                                                                                     83.71   0.27   LO
  ID087   MOL004959   1-Methoxyphaseollidin                                                                                                                                                           69.98   0.64   LO
  ID088   MOL004941   (2R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-one                                                                                                                                 71.12   0.18   LO
  ID089   MOL004914   1,3-dihydroxy-8,9-dimethoxy-6-benzofurano\[3,2-c\]chromenone                                                                                                                    62.9    0.53   LO
  ID090   MOL004912   Glabrone                                                                                                                                                                        52.51   0.5    LO
  ID091   MOL004910   Glabranin                                                                                                                                                                       52.9    0.31   LO
  ID092   MOL004907   Glyzaglabrin                                                                                                                                                                    61.07   0.35   LO
  ID093   MOL004904   licopyranocoumarin                                                                                                                                                              80.36   0.65   LO
  ID094   MOL004891   shinpterocarpin                                                                                                                                                                 80.3    0.73   LO
  ID095   MOL004885   licoisoflavanone                                                                                                                                                                52.47   0.54   LO
  ID096   MOL004879   Glycyrin                                                                                                                                                                        52.61   0.47   LO
  ID097   MOL004863   3-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-(3-methylbut-2-enyl)chromone                                                                                                            66.37   0.41   LO
  ID098   MOL004856   Gancaonin A                                                                                                                                                                     51.08   0.4    LO
  ID099   MOL004855   Licoricone                                                                                                                                                                      63.58   0.47   LO
  ID100   MOL004849   3-(2,4-dihydroxyphenyl)-8-(1,1-dimethylprop-2-enyl)-7-hydroxy-5-methoxy-coumarin                                                                                                59.62   0.43   LO
  ID101   MOL004838   8-(6-hydroxy-2-benzofuranyl)-2,2-dimethyl-5-chromenol                                                                                                                           58.44   0.38   LO
  ID102   MOL004835   Glypallichalcone                                                                                                                                                                61.6    0.19   LO
  ID103   MOL004829   Glepidotin B                                                                                                                                                                    64.46   0.34   LO
  ID104   MOL004824   (2S)-6-(2,4-dihydroxyphenyl)-2-(2-hydroxypropan-2-yl)-4-methoxy-2,3-dihydrofuro\[3,2-g\]chromen-7-one                                                                           60.25   0.63   LO
  ID105   MOL004820   kanzonols W                                                                                                                                                                     50.48   0.52   LO
  ID106   MOL004810   glyasperin F                                                                                                                                                                    75.84   0.54   LO
  ID107   MOL004808   glyasperin B                                                                                                                                                                    65.22   0.44   LO
  ID108   MOL003656   Lupiwighteone                                                                                                                                                                   51.64   0.37   LO
  ID109   MOL001484   Inermine                                                                                                                                                                        75.18   0.54   LO
  ID110   MOL000500   Vestitol                                                                                                                                                                        74.66   0.21   LO
  ID111   MOL000392   formononetin                                                                                                                                                                    69.67   0.21   LO
  ID112   MOL000239   Jaranol                                                                                                                                                                         50.83   0.29   LO

medsci-08-00001-t002_Table 2

###### 

The topological properties of key components.

  Herb       MOL Name                MOL ID      Degree
  ---------- ----------------------- ----------- --------
  FR PR AT   Beta-sitosterol         MOL000358   49
  PR         Kaempferol              MOL000422   44
  AC         L-SPD                   MOL012922   44
  AT         Cavidine                MOL002670   43
  AC AT      Stigmasterol            MOL000449   39
  AC         Estrone                 MOL010921   34
  AC         Machiline               MOL007207   32
  LO         Shinpterocarpin         MOL004891   30
  LO         Formononetin            MOL000392   30
  LO         Naringenin              MOL004328   29
  LO CR      1-Methoxyphaseollidin   MOL004959   28
  LO         Licoagrocarpin          MOL005003   28

medsci-08-00001-t003_Table 3

###### 

The Topological Properties of Targets.

  Target ID   Gene Name   Protein Name                                       Degree
  ----------- ----------- -------------------------------------------------- --------
  P10275      AR          Androgen receptor                                  83
  P03372      ESR1        Estrogen receptor                                  74
  P00918      CA2         Carbonic anhydrase 2                               60
  P37231      PPARG       Peroxisome proliferator-activated receptor gamma   56
  P35354      PTGS2       Prostaglandin G/H synthase 2                       56
  P35228      NOS2        Nitric oxide synthase, inducible                   53
  P00734      F2          Prothrombin                                        49
  P27487      DPP4        Dipeptidyl peptidase 4                             49
  Q92731      ESR2        Estrogen receptor beta                             47
  Q07785      CRK2        Cell division control protein 2 homolog            45
  P49841      GSK3B       Glycogen synthase kinase-3 beta                    46
  O14757      CHEK1       Serine/threonine-protein kinase Chk1               45
  P18031      PTPN1       Tyrosine-protein phosphatase non-receptor type 1   43
  Q16539      MAPK14      Mitogen-activated protein kinase 14                39
  P07900      HSP90AA1    Heat shock protein HSP 90-alpha                    38
  P08238      HSP90AB1    Heat shock protein HSP 90-beta                     37
  P23219      PTGS1       Prostaglandin G/H synthase 1                       32
  P00742      F10         Coagulation factor X                               31
  Q14524      SCN5A       Sodium channel protein type 5 subunit alpha        30

medsci-08-00001-t004_Table 4

###### 

Key components of XQD for lung cancer (LC) treatment.

  Herb       MOL ID      MOL Name                                                                                                Degree
  ---------- ----------- ------------------------------------------------------------------------------------------------------- --------
  FR PR AT   MOL000358   Beta-sitosterol                                                                                         17
  PR         MOL000422   Kaempferol                                                                                              14
  AT         MOL002670   Cavidine                                                                                                13
  CR LO      MOL004328   Naringenin                                                                                              12
  LO         MOL000392   Formononetin                                                                                            11
  AC         MOL012922   l-SPD                                                                                                   11
  AT         MOL002714   Baicalein                                                                                               10
  AT AC      MOL000449   Stigmasterol                                                                                            10
  LO         MOL005003   Licoagrocarpin                                                                                          10
  LO         MOL004959   1-Methoxyphaseollidin                                                                                   10
  LO AC      MOL004908   Glabridin                                                                                               10
  LO         MOL004891   Shinpterocarpin                                                                                         10
  AC         MOL004841   Licochalcone B                                                                                          10
  LO         MOL001484   Inermine                                                                                                10
  AC         MOL010921   Estrone                                                                                                 10
  AC PR      MOL000492   (+)-catechin                                                                                            9
  CR         MOL005828   Nobiletin                                                                                               9
  LO AC      MOL005017   Phaseol                                                                                                 9
  LO         MOL005000   Gancaonin G                                                                                             9
  LO         MOL004941   (2R)-7-hydroxy-2-(4-Hydroxyphenyl)chroman-4-one                                                         9
  LO         MOL004849   3-(2,4-dihydroxyphenyl)-8-(1,1-Dimethylprop-2-enyl)-7-hydroxy-5-methoxy-coumarin                        9
  LO         MOL004835   Glypallichalcone                                                                                        9
  LO         MOL004829   Glepidotin B                                                                                            9
  LO         MOL004824   (2S)-6-(2,4-dihydroxyphenyl)-2-(2-hydroxypropan-2-yl)-4-methoxy-2,3-dihydrofuro\[3,2-g\]chromen-7-one   9
  AC         MOL007207   Machiline                                                                                               9
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###### 

Direct Action of 14 LC Therapeutic targets.

  Types of Action   Degree   Uniprot ID   Gene Name
  ----------------- -------- ------------ -----------
  Direct action     75       P03372       ESR1
  Direct action     45       O14757       CHEK1
  Direct action     40       Q16539       MAPK14
  Direct action     28       P07550       ADRB2
  Direct action     16       P29474       NOS3
  Direct action     14       P35968       KDR
  Direct action     11       P35372       OPRM1
  Direct action     6        P10415       BCL2
  Direct action     3        P08588       ADRB1
  Direct action     1        P27169       PON1
  Direct action     1        P14416       DRD2
  Direct action     1        P05164       MPO
  Direct action     1        P03956       MMP1
  Direct action     1        P01130       LDLR

medsci-08-00001-t006_Table 6

###### 

Indirect action of 27 LC Therapeutic Targets.

  Types of Action   Degree   Uniprot ID   Gene Name
  ----------------- -------- ------------ -----------
  Indirect action   5        P60568       IL2
  Indirect action   5        O14746       TERT
  Indirect action   4        Q9UJU2       LEF1
  Indirect action   3        Q03468       ERCC6
  Indirect action   3        P69905       HBA2
  Indirect action   2        P62736       ACTA2
  Indirect action   2        P16473       TSHR
  Indirect action   2        P04035       HMGCR
  Indirect action   2        P02741       CRP
  Indirect action   1        Q9UBP4       DKK3
  Indirect action   1        Q9H3N8       HRH4
  Indirect action   1        Q9H3D4       TP63
  Indirect action   1        Q14790       CASP8
  Indirect action   1        Q12988       HSPB3
  Indirect action   1        P84022       SMAD3
  Indirect action   1        P57071       PRDM15
  Indirect action   1        P42345       MTOR
  Indirect action   1        P35568       IRS1
  Indirect action   1        P30874       SSTR2
  Indirect action   1        P25391       LAMA1
  Indirect action   1        P18074       ERCC2
  Indirect action   1        P08183       ABCB1
  Indirect action   1        P05556       ITGB1
  Indirect action   1        P04626       ERBB2
  Indirect action   1        P01889       HLA-B
  Indirect action   1        P00519       ABL1
  Indirect action   1        O60469       DSCAM

medsci-08-00001-t007_Table 7

###### 

Expression of 8 LC treatment targets in 14 immune tissues and cells.

  Name                  HLA-B   CASP8   MAPK14   SMAD3   ACTA2   ADRB2   BCL2   LEF1
  --------------------- ------- ------- -------- ------- ------- ------- ------ ------
  **Bone Marrow**       268     6       5        4       8       10      5      4
  **Whole Blood**       689     12      13       4       9       25      6      9
  **Lymph Node**        316     8       3        4       23      3       6      8
  **Thymus**            229     6       3        4       17      2       4      35
  **Tonsil**            302     6       3        4       11      3       5      6
  **Myeloid**           630     11      21       5       9       22      6      4
  **Monocytes**         577     9       13       5       8       9       5      4
  **Dentritic Cells**   558     8       10       6       6       6       5      4
  **NK cells**          716     13      10       5       8       41      7      5
  **T Cells(CD+4)**     514     16      7        7       6       5       11     30
  **T Cells(CD+8)**     512     15      7        5       7       14      8      27
  **B-Lymphoblasts**    410     7       8        5       12      3       9      4
  **B Cells**           411     8       5        8       7       3       11     4
  **Endothelial**       154     6       5        4       5       3       6      4
